MADISON, Wis. – Voximetry, a pioneer in advanced technology to enable personalized treatments for late–stage cancer patients, has appointed Fred Wilson as Vice President of Scientific Affairs. Mr. Wilson is a seasoned Medical Physicist with over 20 years of experience spanning the pharmaceutical development industry, healthcare, and consultancy. He has a proven track record in crafting effective scientific strategies and facilitating successful collaborations between academia, healthcare and industry.
“Deep scientific insight is core to our company values, and Fred’s exceptional knowledge of radiopharmaceutical trials, medical imaging, and the physics of dosimetry really deepen and expand our expertise to better serve our pharma development partners and expand our clinical collaboration research,” said Dr. Sue Wallace, CEO of Voximetry. “Based on Torch, the most advanced and accurate dosimetry software for radiopharmaceutical therapy, Fred and the community now have the necessary tool to accelerate development of effective radiopharmaceuticals and establish Absorbed Dose as the next imaging biomarker.”
Before joining Voximetry, Mr. Wilson led the medical physics functions at Blue Earth Diagnostics/Therapeutics and then at Telix Pharmaceuticals. Wilson began his career as a medical physicist with the UK National Health Service (NHS) and subsequently held roles focused on applying medical imaging techniques to early clinical studies of novel drugs, with significant contributions at major pharmaceutical companies including GSK and Pfizer.
He currently serves on the National Measurement System’s Life Sciences and Health Programme Expert Group (NMS LS&H PEG) for the UK Government’s Department for Science, Innovation and Technology (DSIT) and co-chairs the Strategic Advisory Board of the Postgraduate Institute (PGI) at the UK National Physical Laboratory (NPL).
Mr. Wilson holds an MA and MSci in Natural Sciences from the University of Cambridge and an MSc in Medical Physics from the University of Exeter. He is a Fellow of the Institute of Physics (IoP) and the Institute of Physics and Engineering in Medicine (IPEM). An advocate for equity, diversity and inclusion, Mr. Wilson has mentored students at London’s charity Generating Genius. He enjoys music and has performed on several original recordings available on Spotify.
ABOUT VOXIMETRY
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
ABOUT TORCH
Torch® Dose Assessment software is a proprietary product developed by Voximetry and approved for clinical use by the FDA. Torch design and development continues to be supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA221491 and 2R44CA291564. The product is solely the responsibility of Voximetry and does not represent the official views of the National Institutes of Health.